The CellBox-2 mission to the International Space Station: thyroid cancer cells in space

Daniela Melnik, Marcus Krüger, Herbert Schulz, Sascha Kopp, Markus Wehland, Johann Bauer, Bjorn Baselet, Randy Vermeesen, Sarah Baatout, Thomas J. Corydon, Manfred Infanger, Daniela Grimm

    Research outputpeer-review


    A spaceflight to the International Space Station (ISS) is a dream of many researchers. We had the chance to investigate the effect of real microgravity (CellBox-2 Space mission) on the transcriptome and proteome of FTC-133 human follicular thyroid cancer cells (TCC). The cells had been sent to the ISS by a Falcon 9 rocket of SpaceX CRS-13 from Cape Canaveral (United States) and cultured in six automated hardware units on the ISS before they were fixed and returned to Earth.
    Multicellular spheroids (MCS) were detectable in all spaceflight hardware units. The VCL, PXN, ITGB1, RELA, ERK1 and ERK2 mRNA levels were significantly downregulated after 5 days in space in adherently growing cells (AD) and MCS compared with ground controls (1g), whereas the MIK67 and SRC mRNA levels were both suppressed in MCS. By contrast, the ICAM1, COL1A1 and IL6 mRNA levels were significantly upregulated in AD cells compared with 1g and MCS. The protein secretion measured by multianalyte profiling technology and enzyme-linked immunosorbent assay (AngiogenesisMAP®, extracellular matrix proteins) was not significantly altered, with the exception of elevated angiopoietin 2. TCC in space formed MCS, and the response to microgravity was mainly anti-proliferative. We identified ERK/RELA as a major microgravity regulatory pathway.
    Original languageEnglish
    Article number22168777
    Pages (from-to)1-20
    Number of pages20
    JournalInternational Journal of Molecular Sciences
    StatePublished - 16 Aug 2021

    Cite this